Cargando…
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation
Therapies targeting the tyrosine kinase activity of Epidermal Growth Factor Receptor (EGFR) have been proven to be effective in treating a subset of non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Inevitably these patients develop resistance to the EGFR-targeted tyro...
Autores principales: | Kim, Nayoung, Cho, Ahye, Watanabe, Hideo, Choi, Yoon-La, Aziz, Meraj, Kassner, Michelle, Joung, Je-Gun, Park, Angela KJ, Francis, Joshua M., Bae, Joon Seol, Ahn, Soo-min, Kim, Kyoung-Mee, Park, Joon Oh, Park, Woong-Yang, Ahn, Myung-Ju, Park, Keunchil, Koo, Jaehyung, Yin, Hongwei Holly, Cho, Jeonghee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924679/ https://www.ncbi.nlm.nih.gov/pubmed/26883194 http://dx.doi.org/10.18632/oncotarget.7318 |
Ejemplares similares
-
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019) -
Exome and transcriptome sequencing identifies loss of PDLIM2 in metastatic colorectal cancers
por: Oh, Bo Young, et al.
Publicado: (2017) -
Structure and mechanism of activity-based inhibition of the EGF-Receptor by Mig6
por: Park, Eunyoung, et al.
Publicado: (2015) -
Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015) -
Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants
por: Park, Angela K.J., et al.
Publicado: (2015)